Akademik Veri Yönetim Sistemi
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, cilt.37, sa.e23440, ss.1-10, 2023 (SCI-Expanded, Scopus)
The body can host the spread of prostate cancer cells. Metastases from prostate cancer are more frequently seen in the brain, liver, lungs, and lymph nodes. A well‐known antidiabetic drug, metformin, is also known to have antitumor effects. Our study focuses on the evaluation of potential metformin protective effects on brain and cerebellum damage in streptozotocin (STZ)‐induced diabetic and Dunning prostate cancer models. In this investigation, six groups of male Copenhagen rats were created: control, diabetic (D), cancer (C), diabetic + cancer (DC), cancer +metformin, and diabetic + cancer + metformin. The brain and cerebellum tissues of the rats were taken after sacrifice. Oxidative stress markers including reducedglutathione level, lipid peroxidation, glutathione reductase, glutathione peroxidase,glutathione‐S‐transferase, catalase, superoxide dismutase activities, reactive oxygenspecies, total oxidant and total antioxidant status, lactate dehydrogenase, xanthineoxidase, acetylcholinesterase activities, protein carbonyl contents, nitric oxideand OH‐proline levels, sodium potassium ATPase, carbonic anhydrase, andglucose‐6‐phosphate dehydrogenase activities; glycoprotein levels including hexose,hexosamine, fucose, and sialic acid levels; and histone deacetylase activity as acancer marker were determined. Oxidative stress markers were impaired and glycoprotein levels and histone deacetylase activity were increased in the D, C, and DC groups. Metformin therapy reversed these effects. Metformin was found to protect the brain and cerebellum of STZ‐induced diabetic rats with Dunning prostate cancer from harm caused by MAT‐Lylu metastatic cells.